Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]
Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.
Adding pembrolizumab to chemotherapy with or without bevacizumab significantly extends overall survival (OS) by 8 months in women with recurrent, persistent or metastatic cervical cancer, according to the KEYNOTE-826 study presented at ESMO 2021.
Palbociclib plus letrozole as first-line treatment improves progression-free survival (PFS) vs placebo plus letrozole in postmenopausal Asian patients with advanced oestrogen receptor (ER)–positive and HER2-negative breast cancer (BC), primary results of the phase III PALOMA-4 study have shown.
Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.
Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.
A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.
Interim results of two phase III ORIENT trials presented at ESMO 2021 underscore the potential of a combination regimen comprising the PD-1 inhibitor sintilimab and chemotherapy (CT) as a first-line therapeutic alternative for gastrointestinal cancers, particularly advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (SCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
Trastuzumab deruxtecan (T-Dxd) provides a highly clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs trastuzumab emtansine (T-DM1) in second-line treatment of HER2-positive metastatic breast cancer (mBC), results of the phase III DESTINY-Breast03 trial have shown.